ADPT
NASDAQAdaptive Biotechnologies Corporation
Price$24.03-0.91 (-3.65%)
01:30 PM07:45 PM
News · 26 weeks53+17%
2026-04-262026-10-18
Mix2690d
- Insider17(65%)
- SEC Filings4(15%)
- Other3(12%)
- Earnings2(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Adaptive Biotechnologies Corporation4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- PRAdaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 h
- INSIDERSEC Form 4 filed by Adaptive Biotechnologies Corporation4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Adaptive Biotechnologies Corporation4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Adaptive Biotechnologies Corporation4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Adaptive Biotechnologies Corporation4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERSEC Form 4 filed by Adaptive Biotechnologies Corporation4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- PRAdaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of CureSEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scotland, on behalf of IMS and the International Myeloma Working Group (IMWG). Long considered an incurable disease, multiple myeloma is entering a new phase in which some patients are remaining free of detectable disease for years after treatment ends. Significant advances in
- INSIDERChief People Officer Lo Francis exercised 105,560 shares at a strike of $9.57 and sold $3,238,004 worth of shares (115,406 units at $28.06) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 220,867 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $32,265 worth of shares (1,195 units at $27.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.30% to 395,794 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- PRAdaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted significant updates to the National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma that further establish highly sensitive minimal (or meas
- INSIDERDirector Owen Katey Einterz gifted 12,539 shares, decreasing direct ownership by 16% to 66,100 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- PRAdaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceSEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 15, 2026, at 1:50 p.m. Pacific Time / 4:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.adapti
- INSIDERDirector Owen Katey Einterz sold $249,990 worth of shares (9,615 units at $26.00), decreasing direct ownership by 11% to 78,639 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERDirector Hershberg Robert exercised 15,000 shares at a strike of $6.32 and sold $748,208 worth of shares (30,664 units at $24.40), decreasing direct ownership by 25% to 46,683 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERCEO and Chairman Robins Chad M exercised 600,000 shares at a strike of $6.55 and sold $14,882,166 worth of shares (600,000 units at $24.80) (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERDirector Neupert Peter M sold $3,135,850 worth of shares (124,690 units at $25.15) and exercised 15,000 shares at a strike of $6.32, decreasing direct ownership by 46% to 130,625 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECSEC Form 144 filed by Adaptive Biotechnologies Corporation144 - Adaptive Biotechnologies Corp (0001478320) (Subject)
- SECSEC Form 144 filed by Adaptive Biotechnologies Corporation144 - Adaptive Biotechnologies Corp (0001478320) (Subject)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $75,000 worth of shares (3,000 units at $25.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.75% to 396,989 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECSEC Form 10-Q filed by Adaptive Biotechnologies Corporation10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $31,176 worth of shares (1,299 units at $24.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.32% to 399,989 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECAdaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
- PRAdaptive Biotechnologies Reports Second Quarter 2026 Financial ResultsSEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026. "We delivered an exceptional second quarter, driven by expanding growth and profitability in MRD, including both our clinical and biopharma businesses," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "The combination of our operating performance, fortified balance sheet and plan to separate the Immune
- INSIDERChief Scientific Officer Robins Harlan S exercised 284,800 shares at a strike of $6.55 and sold $10,780,409 worth of shares (492,400 units at $21.89) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 812,058 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
ADPT FAQ
7 questionsWhat does Adaptive Biotechnologies Corporation do?
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and...Where does ADPT stock trade?
Adaptive Biotechnologies Corporation (ADPT) is listed on NASDAQ.What sector and industry is ADPT in?
Adaptive Biotechnologies Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Adaptive Biotechnologies Corporation go public?
Adaptive Biotechnologies Corporation (ADPT) completed its IPO in 2019.What are analysts saying about ADPT?
Adaptive Biotechnologies Corporation has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $2100.00 price target on 2025-12-02. Recent price targets range from $800.00 to $2100.00.What companies are similar to ADPT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ADPT side-by-side with any of them on Quantisnow.How can I track ADPT on Quantisnow?
Quantisnow aggregates Adaptive Biotechnologies Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADPT to receive live email and push alerts on every new disclosure.